<SEC-DOCUMENT>0001144204-13-056490.txt : 20131023
<SEC-HEADER>0001144204-13-056490.hdr.sgml : 20131023
<ACCEPTANCE-DATETIME>20131023172020
ACCESSION NUMBER: 0001144204-13-056490
CONFORMED SUBMISSION TYPE: 6-K
PUBLIC DOCUMENT COUNT: 4
CONFORMED PERIOD OF REPORT: 20131023
FILED AS OF DATE: 20131023
DATE AS OF CHANGE: 20131023
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Can-Fite BioPharma Ltd.
CENTRAL INDEX KEY: 0001536196
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 6-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-55041
FILM NUMBER: 131166335
BUSINESS ADDRESS:
STREET 1: 10 BAREKET STREET, KIRYAT MATALON
STREET 2: P.O. BOX 7537
CITY: PETACH TIKVA
STATE: L3
ZIP: 4951778
BUSINESS PHONE: 972 39241114
MAIL ADDRESS:
STREET 1: 10 BAREKET STREET, KIRYAT MATALON
STREET 2: P.O. BOX 7537
CITY: PETACH TIKVA
STATE: L3
ZIP: 4951778
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v357866_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="margin: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>
<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16<BR>
Under the Securities Exchange Act of 1934</P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of October 2013</P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">000-55041<BR>
(Commission File Number)</P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>
<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CAN-FITE BIOPHARMA LTD.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of Registrant as specified in
its charter)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><BR>
<B>10 Bareket Street</B><BR>
<B>Kiryat Matalon, P.O. Box 7537</B><BR>
<B>Petach-Tikva 4951778, Israel</B><BR>
(Address of principal executive offices)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Indicate by check mark whether the registrant
files or will file annual reports under cover<BR>
Form 20-F or Form 40-F.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F <FONT STYLE="font-family: Wingdings">þ</FONT> Form 40-F
<FONT STYLE="font-family: Wingdings">¨</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by<BR>
Regulation S-T Rule 101(b)(1): ____</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by<BR>
Regulation S-T Rule 101(b)(7): ____</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
<!-- Field: Page; Sequence: 1 -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">On
October 22, 2013, Can-Fite BioPharma Ltd. (the “Company”) issued press releases in Israel and the United
States announcing, among other things, that the Company estimates that the results of its Phase II study in Europe and
Israel for its drug CF101 for the treatment of Rheumatoid Arthritis and the results of a Phase III study for its drug CF101
for the treatment of Dry Eye Syndrome, which OphthaliX Inc., a subsidiary of the Company is conducting, are both expected to
be published during the last two weeks of December 2013. A translation of the press release issued in Israel is attached
hereto as Exhibit 99.1 and is incorporated herein by reference. A copy of the press release issued in the United States (the
“U.S. Press Release”) is attached hereto as Exhibit 99.2 and is incorporated herein by reference.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
The description of the Company’s existing out-license agreements included in the U.S. Press Release
should be read in conjunction with the descriptions of such agreements contained in the Form 20-F filed by the Company with the
United States Securities and Exchange Commission on September 9, 2013, as amended by Amendment No. 1 on Form 20-F/A filed by the
Company with the United States Securities and Exchange Commission on September 10, 2013.
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Exhibit
Index</P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit
No.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P></TD>
<TD STYLE="width: 86%; padding-right: 5.4pt; padding-left: 5.4pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Description</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">99.1</TD>
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">Press Release, dated October 22,
2013, issued by the Company in Israel</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">99.2</TD>
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">Press Release, dated October 22, 2013, issued by the Company in the United States</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<!-- Field: Page; Sequence: 3; Value: 2 -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SIGNATURES</P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD> </TD>
<TD COLSPAN="2"><B>Can-Fite BioPharma Ltd.</B></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 55%">Date: October 23, 2013</TD>
<TD STYLE="width: 3%"> </TD>
<TD STYLE="width: 42%"> </TD></TR>
<TR STYLE="vertical-align: top">
<TD> </TD>
<TD>By:</TD>
<TD STYLE="border-bottom: Black 1pt solid">/s/ Motti Farbstein</TD></TR>
<TR STYLE="vertical-align: top">
<TD> </TD>
<TD> </TD>
<TD>Motti Farbstein</TD></TR>
<TR STYLE="vertical-align: top">
<TD> </TD>
<TD> </TD>
<TD>Chief Operating and Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
<TD> </TD>
<TD> </TD>
<TD> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>
<!-- Field: Page; Sequence: 4; Options: Last -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<!-- Field: /Page -->
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v357866_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="margin: 0"> </P>
<P STYLE="margin: 0; text-align: left"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="background-color: white"><B>Exhibit
99.1</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B> </B><IMG SRC="image_001.jpg" ALT=""></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>Can-Fite
BioPharma Announces Expected Clinical Activity Milestones through the end of 2013 and Listing on Major US Stock Exchange</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>Results
from Two Clinical Trials at advanced stages is expected in last two weeks of 2013;</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Symbol">·	 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Conclusion
and announcement of final results of Dry Eye Syndrome Phase III trial, with an estimated market share of $2 Billion dollars;</B></FONT></P>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">·	</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B> Conclusion
and announcement of final results of 	Rheumatoid Arthritis Phase II trial, with an estimated market share of $12 Billion dollars;</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.25in"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>The
company is seeking to have its ADRs listed on the NYSE MKT prior to publication of the above trials</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black; background-color: white"><B>Petach
Tikva, Israel - October 22, 2013 - </B>Can-Fite BioPharma (TASE: CFBI), (OTC:CANFY), a biotechnology company engaged in the development
and marketing of molecule drugs that address inflammatory and liver diseases, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">announced
today its expected clinical activity milestones through the end of 2013</FONT> as well as its activity <FONT STYLE="font-family: Times New Roman, Times, Serif">to
have its American Depository Receipts (ADRs) listed on the NYSE MKT prior to publication of the above trials. </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">·</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Uplisting to NYSE MKT:</U> Following
the commencement of trading in Can-Fite's Level II ADRs in the U.S. in September 2013, Can-Fite is now actively seeking to have
its ADRs listed on the NYSE MKT, and assumes that this process will be completed shortly prior to the publication of the results
in the above two clinical trials.</FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">·</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black; background-color: white"><U>Dry
Eye Syndrome </U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif">Phase III Results:</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif">
The Company anticipates that during the last 2 weeks of December 2013, it will conclude and announce the results of its Phase III
trial for CF101 in the treatment of dry eye syndrome, which is being conducted by OphthaliX Inc. (OTCQB:OLPI), a subsidiary of
Can-Fite. The estimated market share of this drug was $1.6 billion in 2010 and is expected to grow to $5.5 billion by 2022. </FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>
<!-- Field: Page; Sequence: 1 -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<!-- Field: /Page -->
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><IMG SRC="image_001.jpg" ALT=""> </P>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">·</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Rheumatoid Arthritis Phase II Results</U>:
Can-Fite estimates the results of its Phase II study for its drug CF101 for the treatment of rheumatoid arthritis will be concluded
and announced during the last 2 weeks of December 2013.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">The estimated
market share of this drug was $12 billion in 2010 and is expected to grow to $18 billion by 2020.</FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">·</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Beyond 2013 – Additional Clinical
Trials and timetables</U>: In addition to the study results slated for release in December, Can-Fite is conducting four other trials,
including a Phase III trial for Psoriasis and Phase II trials for liver cancer, glaucoma and uveitis. </FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Professor
Pnina Fishman,</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Can-Fite CEO said today that “we are excited
about the imminent completion of two advanced clinical trials this year with respect to two drugs to be used in major markets,
which generate a lot of interest among the medical community as well as the global pharmaceutical industry. Subject to successful
completion of the clinical trials and regulatory approvals, we believe that listing of our stock at the NYSE MKT will assist the
company in preparing for possible marketing and monetizing the business potential of these two crucial drugs, as well as other
products being developed by Can-Fite and its subsidiary</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">OphthaliX
Inc., which are at <FONT STYLE="color: black; background-color: white">advanced stages of clinical development.”</FONT></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><U>About
Can-Fite BioPharma Ltd.</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Can-Fite
BioPharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (the “TASE”)
(TASE: CFBI). Level II American Depository Receipts of the company are traded on the U.S. Over-the-Counter Markets (the “OTC
Markets”) (OTCQB: CANFY). Can-Fite, which commenced business activity in 2000, was founded by Professor Pnina Fishman, Ph.D.,
researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys
in Israel. Professor Fishman serves as the Chief Executive Officer of Can-Fite. Professor Fishman founded Can-Fite on the basis
of her scientific findings and Can-Fite is focused on the development of small molecule orally bioavailable drugs, in particular,
ligands that bind to the A3 adenosine receptor. Such drugs mediate anti-inflammatory and anti-cancer effects and are suggested
as a biological predictive marker. Can-Fite’s lead drug candidate, CF101, is in advanced clinical development for the treatment
of autoimmune inflammatory diseases. Can-Fite’s second drug candidate, CF102, is being developed for the treatment
of liver diseases including liver cancer and Hepatitis C. Can-Fite is highly experienced in clinical trials and as of today,
hundreds of patients have participated in such trials conducted by the company. Can-Fite previously licensed its activity in the
ophthalmic field to OphthaliX Inc., its subsidiary. </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
<!-- Field: Page; Sequence: 2; Options: Last -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="margin: 0; text-align: left"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>v357866_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="margin: 0"> </P>
<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.2</B></P>
<P STYLE="margin: 0"> </P>
<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT=""> </P>
<P STYLE="margin: 0"> <FONT STYLE="background-color: white"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B> </B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt; background-color: white"><B>Can-Fite
BioPharma Announces Clinical and Corporate Developments for Near-Term Events</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><I>Potential
uplisting on to NYSE MKT and results from two clinical trials expected by end of 2013</I></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black; background-color: white"><B>Petach
Tikva, Israel - October 22, 2013 - </B>Can-Fite BioPharma (TASE: CFBI), (OTCQB:CANFY), a biotechnology company with a pipeline
of proprietary small molecule drugs that address inflammatory and cancer diseases, </FONT>announced today a series of clinical
and corporate developments, with key events expected by the second week of December, 2013.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Near term events include:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">·</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Uplisting to NYSE MKT:</U> Following
the commencement of trading in Can-Fite's Level II ADRs in the U.S. in September 2013, Can-Fite is now actively seeking to have
its shares listed on the NYSE MKT. The Company is currently in the application process and believes e the listing is imminent.
</FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">·</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Rheumatoid Arthritis Phase II Results:</U>
Can-Fite <FONT STYLE="color: black; background-color: white">estimates the results of its </FONT>Phase II study in Europe and Israel
for its drug CF101 for the treatment of rheumatoid arthritis will be concluded and announced during the last 2 weeks of December
2013.</FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">·</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black; background-color: white"><U>Dry
Eye Syndrome </U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif">Phase III Results:</FONT></U><FONT STYLE="font-family: Times New Roman, Times, Serif">
The Company also anticipates that during the last 2 weeks of December 2013, it will conclude and announce results of its Phase
III trial for CF101 in the treatment of dry eye syndrome, which is being conducted by OphthaliX Inc. (OTCQB:OLPI), a subsidiary
of Can-Fite.</FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="background-color: white">Ongoing
corporate and clinical developments: </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">·</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black; background-color: white"><U>Licensing
Deals:</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> To date, Can-Fite has executed two out-licensing deals
in the Asian market for $21.8 million in up-front fees based on milestone payments, with additional royalties to be earned following
approvals and commercialization. </FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">·</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black; background-color: white"><U>Multiple
Additional Clinical Trials:</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> In addition to the study results
slated for release in December, Can-Fite is conducting four other trials including Phase III trials for Psoriasis, Phase II trials
for liver cancer, Phase II trials for glaucoma, and Phase II trials for uveitis. </FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">·</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black; background-color: white"><U>Market
Addressed:</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Collectively, the markets addressed by Can-Fite’s
drugs currently in various stages of clinical trials tops $30 billion. </FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>
<!-- Field: Page; Sequence: 1 -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<!-- Field: /Page -->
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT=""> </P>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">“We are making significant advancements
with our clinical development programs. This drives the progress in our corporate development which includes a larger presence
for our Company in the U.S. markets. The commencement of trading for our Level II ADRs was an important first step to show our
commitment to the U.S. market, both for our products and for our U.S.-based investors. We’ve been in very productive talks
with the NYSE MKT and anticipate Can-Fite being listed there before the end of the calendar year,” stated Can-Fite CEO Dr.
Pnina Fishman.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Can-Fite’s
drugs are at advanced stages of clinical development in the U.S., Europe and Israel. The Company has also established a portfolio
of patent families covering methods of use for treatment of a number of inflammatory diseases. The Company currently maintains
14 patent families that include 74 international patents issued and pending, and its science is well founded with articles in 48
peer reviewed journals.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><U>About
CF101</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">CF101,
an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug which demonstrated efficacy
and an excellent safety profile in clinical studies. Through a service arrangement with its parent, Can-Fite, OphthaliX currently
develops CF101 for the treatment of ophthalmic indications, including dry eye syndrome (Phase III), glaucoma (Phase II) and uveitis
(initiating Phase II). CF101 is also developed by Can-Fite for the treatment of autoimmune inflammatory diseases, including, but
not limited to, rheumatoid arthritis (Phase IIb) and psoriasis (Phase II/III).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><U>About
Can-Fite BioPharma Ltd.</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Can-Fite
BioPharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (the “TASE”)
(TASE: CFBI). Level II American Depository Receipts of the company are traded on the U.S. Over-the-Counter Markets (the “OTC
Markets”) (OTCQB: CANFY). Can-Fite, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher
in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys in Israel.
Dr. Fishman serves as the Chief Executive Officer of Can-Fite. Dr. Fishman founded Can-Fite on the basis of her scientific findings,
and Can-Fite is focused on the development of small molecule orally bioavailable drugs, in particular, ligands that bind to the
A3 adenosine receptor. Such drugs mediate anti-inflammatory and anti-cancer effects and are suggested as a biological predictive
marker. Can-Fite’s lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases.
Can-Fite’s CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed
for the treatment of inflammation and sexual dysfunction. To date, more than 700 patients have participated in clinical trials
conducted by Can-Fite. Can-Fite previously licensed its activity in the ophthalmic field to OphthaliX Inc., in which it holds a
controlling interest and which is currently listed on the OTC Markets (OTCQB: OPLI).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>
<!-- Field: Page; Sequence: 2 -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"> </FONT></P>
<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT=""> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><U>Safe
Harbor Statement</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This
press-release contains forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among
other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In
addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing.
Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,”
“intend,” “plan,” “may,” “should” or “anticipate” or their negatives
or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical
or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite
with the U.S. Securities and Exchange Commission (the “<U>SEC</U>”), press releases or oral statements made by or with
the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have
not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results
to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s
actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements,
including, but not limited to, the factors summarized in Can-Fite’s filings with the SEC and in its periodic filings with
the TASE.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><U>Contact</U></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><BR>
<FONT STYLE="color: black; background-color: white">IRTH Communications</FONT><BR>
<FONT STYLE="color: black; background-color: white">Robert Haag</FONT><BR>
<FONT STYLE="color: Blue; background-color: white"><U>Email Contact</U></FONT><FONT STYLE="color: black; background-color: white"> </FONT><BR>
<FONT STYLE="color: black; background-color: white">1-866-976-IRTH (4784)</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: black; background-color: white"> </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: black; background-color: white"></FONT></P>
<!-- Field: Page; Sequence: 3; Options: Last -->
<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"> </TD></TR></TABLE></DIV>
<!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!^`:,#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^N>\5^-=
M'\'V8FU*<F:0'R;:+F23Z#L/<\4>-/%=MX/\.3:E,!),3Y=O#G'F2'H/IU)]
M@:^6-5U6^UO4Y]1U&X:>ZF.7<]O0`=@.PK:E2Y]7L,[K7_C/XEU5W33C%I5L
M>`(@'E(]W(_D!7$WFO:SJ+%KW5[^X)Z^9<N1^6<5GT5V*$8[(8N3G.3GUS5Z
MSUS5]/8-9:M?VY'3RKEU'Y9K.\Q/[R_G3J=@/1?#_P`9O$NDR(FI,FJVHX82
M@)*![.!R?J#7N?A?Q9I/B[3?MFF3Y*G$L+\21-Z,/Z]#7R/6MX;\1W_A76X=
M4T]_G0XDB)^69.Z-]?T/-8U**DM-Q6/KZBJ&BZO:Z]HUIJED^ZWN8PZYZCU!
M]P<@^XJ_7$(YCX@^(3X9\%:A?Q/LN63R;<]_,?@$?3D_A7S@/''BP`#_`(23
M5/\`P):N]^.VO_:=8L=!B?Y+1/M$P']]N%!^BY/_``*O)*[:,$HW8T;_`/PG
M/BS_`*&35/\`P(:C_A.?%HY'B34\CIFX)K`HK7E789]>^%];3Q%X8T_5DQFY
MA#.!_"XX8?@P(K7KQGX#Z]OMM1\/ROS$WVJ`'^Z>''X':?\`@1KV:N"I'EDT
M2>2_&W7-6T5-$.EZE=67FM-YGD2%-^`F,X],FO)/^$Y\6?\`0R:I_P"!#5Z9
M^T!]SP__`+T_\DKQ2NJBDX+0:-__`(3GQ9_T,FJ?^!#5[?\`"?QTWB?2&TW4
M9M^K62C<['F>/H'^HZ'\#WKYQJ_HFLWGA_6;75;!]MQ;ON`/1QW4^Q'%5.FI
M1L@/L6BLOP[KUGXFT*UU6Q;,4ZY*D\QL/O*?<'BM2N!JV@CQ?XU>(-9T;7-*
MBTS5;NSCDMG9U@E*AB&')Q7F7_"<^+/^ADU3_P`"&KO/CY_R,&C?]>LG_H8K
MR2NZE%<BT&;K^.?%@1L>)-4Z?\_#5]86+,]A;.Q+,T2DD]S@5\8/_JV^E?9N
MG_\`(-M?^N*?R%98A)6L#/E67QQXK$\H'B34P`[`#[0WK3?^$Y\6?]#)JG_@
M0U8<W_'Q+_UT;^9IE=/*NPS?_P"$Y\6?]#)JG_@0U'_"<^+/^ADU3_P(:L`D
M`9)P*;YB?WU_.CE78#H?^$Y\6?\`0R:I_P"!#4?\)SXL_P"ADU3_`,"&KGO,
M3^^OYT>8G]]?SHY5V`[[P5XO\2WOCC1+:ZU[49H);M5DCDG)5ASP16?K7C3Q
M3#KVI11>(=22-+N945;@@*`Y``JGX`=#\0M``92?MJ=_K6?KW_(QZK_U^S?^
MC&J>5<VPB_\`\)SXL_Z&35/_``(:MKP=XP\37GC71+:YU_49H);V-)(WG)5U
M)Y!'I7#5O^!O^1^\/_\`7_%_.G**L]!DUWXW\5I?7*KXCU,*LS@`7#<#<:A_
MX3GQ9_T,FJ?^!#5CWO\`R$+O_KO)_P"A&H*:BNP&_P#\)SXL_P"ADU3_`,"&
MH_X3GQ9_T,FJ?^!#5@44<J[`;_\`PG/BS_H9-4_\"&H_X3GQ9_T,FJ?^!#5@
M44<J[`;_`/PG/BS_`*&35/\`P(:C_A.?%G_0R:I_X$-6!11RKL!WO_"7^)?^
M%>F[_M[4/M/]L"+S?/.[9Y&=N?3/-8/_``G/BS_H9-4_\"&J0?\`),3_`-AP
M?^D]<Y2C%:Z`;_\`PG/BS_H9-4_\"&H_X3GQ9_T,FJ?^!#5@4A90>2!^-/E7
M8#H/^$Y\6?\`0R:I_P"!#4?\)SXL_P"ADU3_`,"&KGMZ_P!X?G1O7^\/SHY5
MV`Z'_A.?%G_0R:I_X$-4EOXW\5M=0J?$>ID&101]H;D9%<UO7^\/SJ6V=?M=
MO\P_UJ=_]H4<J[`?:-%%%>:2?.7QHU]M4\9_V:CYMM,C"``\&5@&8_EM'X&O
M.*T?$%X=1\2:K>DY,]Y*^?8N<?IBLZO1@N6*10$X&3TKW+X=?"6R_LV#6/$E
MO]HGG420V;_<C4\@N/XF/7!X'UKR;PCIJ:OXQT?3Y5W1372"0>J@[F'Y`U]=
MUC7FUHA,HIHFDQP^2FF62Q8QL%NH7\L5YYX\^$>FZG83W_A^U2SU*-2_D1#;
M'/\`[.WHK>A'X^H]1HKFC.47="/BOIU!!'4'C%2VMK<WT@CL[>:YD/188RY_
M05]3P_#KPC#?S7O]AVLMQ-*TK-,#(-S')PK$@<GL*Z.WM;>TB$5M!%#&.B1H
M%'Y"NEXE=$.YYG\&++Q#I.F7^GZOIES:V>\36S3@*<GAUVYR.@/3N:],N;B*
MTM9KF=PD,*&1V/90,D_E4M>=?&?7O[)\$M8QOBXU-_(&.OECES^6!_P*L-:D
M_41X!KNK2Z]KU_JTV=]W,T@!_A7^$?@`!^%9]%&&8A4&YB<*!W/85W[%&E<Z
M)=6WAVPUMQ_HU[/+"G'0ICG\<M_WR:S:^AO&/@X0?!:/3(TS/I4$=P,#.77F
M3\P7KYYJ*<^=7$;W@K73X;\8:;J9;$*2^7/_`-<V^5ORSG\*^M@00"#D'H17
MQ61D$'H:^HOA=KY\0>!+&21]US:C[+/GKN3@'\5VG\:QQ$=I`SB/V@/N>'_]
MZ?\`DE>*5[7^T!]SP_\`[T_\DKQ2M*/P($%%%%;#.^^%?C?_`(177?L=[+C2
M;Y@LN3Q#)T63V'8^V#VKZ6!R,CI7Q61D8/2OH'X.^./[8TW_`(1_4)<W]DF8
M'8\S0CC\2O3Z8]ZY:]/[2$SF?CY_R,&C?]>LG_H8KR2O6_CY_P`C!HW_`%ZR
M?^ABO)"<#)K6C\"`:_\`JV^E?9NG_P#(-M?^N*?R%?.FF>']%\,:':ZUXHM6
MO[^^3S+'2=VU1'VDE/H?3]#SC6_X7)XE693';Z;'"O`A$+$`>F=V:Y<16BW9
M=#MH8"O7CS16GF>63?\`'Q+_`-=&_F:97H\VC:)X\L;F?0;%=*\16Z&9]/C;
M,-VHZF/T;V__`%CSC\Q]:ZZ=2-17B<]6E.E+DFK,ZGX;1I+\1=$CD171IF!5
MAD']VW8U]0?V5IW_`#X6O_?E?\*^4/"6LP^'O%>GZO<122PVLA9DCQN.5(XS
MQWKV+_A?>A_]`C4O_(?_`,56-:$I2T,F>F_V5IW_`#X6O_?E?\*/[*T[_GPM
M?^_*_P"%>9?\+[T/_H$:E_Y#_P#BJ/\`A?>A_P#0(U+_`,A__%5E[*IV%8]/
M33;&)U>.RMT=3D,L2@@_7%?(FO?\C'JO_7[-_P"C&KZN\-:]!XG\/VNL6T,L
M,-P&*I+C<,,5YP2.U?*.O?\`(QZK_P!?LW_HQJUP][NXT9];_@;_`)'[P_\`
M]?\`%_.L"M_P-_R/WA__`*_XOYUT2^%C/;Y?@EX2EFDE8ZCN=BYQ<]R<^E,_
MX4?X1]=1_P#`G_ZU>DT5P>TGW)/(/%'PA\,:/X6U34K4W_VBUMGECWW&5W`9
M&1CD5X57UEX]_P"1`U__`*\9?_037R;750DY)W&@KMOAAX4TWQAXAN['5#/Y
M,5J9E\F38=V]1UQTP37$UZE\!_\`D<M1_P"P>?\`T8E74;4&T!W/_"C_``CZ
MZC_X$_\`UJ/^%'^$?74?_`G_`.M7I-%<7M)]Q'@_Q1\(Z9X.\&6-GI9G\J?4
MO-?SI-YW>41P<=,"O(Z]Z^/?_(MZ3_U^G_T6U>"UV46W"[&@KZ$^"-K;S>!)
M6E@BD;[=*,L@)Z+7SW7=^#OBA?\`@W1&TRVTRVN8VF:;?)(RG+`#&`/:BK%R
MC9`?2/\`9]G_`,^D'_?L?X4?V?9_\^D'_?L?X5X=_P`+\U?_`*`5E_W_`'_P
MH_X7YJ__`$`K+_O^_P#A7-[&H%CW'^S[/_GT@_[]C_"C[!9C_ET@_P"_8_PK
MP[_A?FK_`/0"LO\`O^_^%=7\/?BA?^,O$4NFW.FVUM&ELTP>.1F)(91C!'^U
M2=*:5V(].HHHK(#XL))8D]<\TE7M;M#I^OZE9L,&"[ECQ]'(%4:]-%'8?"P`
M_$O1<_WY,?7RVKZDKY,\!WBV'CW0KAV"H+M48GL&RG_LU?6=<F(^)"84445S
MB"BO']4^-K:3XKU'3WTJ.ZT^VG,*2PR[9#MX8\Y!^;/I74:/\6_"&K[4;4#8
MS'CR[Q/+Y_WN5_6K=.:5[`=Q7S3\8->_MGQU-;1OFWTU/LRXZ;^KG\\#_@->
M^Z[XAM-(\+7VN)-%-#;PLZ,C!E=NB@$>I('XU\C2RR7$TDTSEY96+NQ_B8G)
M/YFML/'5R&AM=5\-]&_MSQ]I5NR[H89/M,N1QMC^89^K;1^-<K7=?#/QAH_@
MR]O[W4K:[FGGC6*+R%4A5SELY(ZG;^5=$[\KL,^EYX8[B"2"50T<BE'4]P1@
MBOCO6=,DT76[[2Y/O6D[Q9]0#P?Q&#^->Z_\+W\-_P#0/U7_`+]Q_P#Q=>2>
M/]>TSQ-XJDU?2X;B%)XD$J3JH.]>,C!/&`OY5A0C*+=T)',5ZC\#M?\`L'B>
MYT:5\0ZA'NC!_P">J<_JN[\A7EU6M,U";2-5M-2MC^^M9EF3W*G./QZ?C6\X
M\T6AGL/[0'W/#_\`O3_R2O%*]B^-]]#J>E>%K^V;=!<I++&?9EC(_G7CM31^
M!"0C'"GZ5VOC?P6VA:=H^MVB$Z=J-I"SXZ0S%`2/HW)'OD>E<4WW&^E?6%CH
M]GK_`,.=/TN_CWV]QIL*MZ@^6N&'H0<$?2E5GR-,#Y0JUIFI7>CZG;:C8RF*
MZMG$D;>_H?4$9!'H:M^(]`O/#&O7.DWH_>0M\D@&!*A^ZX]B/R.1VK*K71H9
MZ!\4/$EKXL7P[JUKA3):2++%G)BD#C<I_IZC!KBM*@CNM9L+:;_537,4;_[I
M<`_H:J4JLR,KHQ5U(96'8CH:48V5D!WGQ'N9;GQ_JHDX6!UAC7LJ*HP!^9/X
MURU=[K=D?'^FQ^*=%03:BD2Q:K81_P"L1U&!(J]U(';L!Z&N#9'20QLC+(#@
MH5(;/TZUXM2+C)IGU^!K0J4(\O16-?PI=367B_1Y[<GS!=QK@=PS!2/Q!(JE
MXXMHK/QWKL$`"Q+>.5`Z#/S$?F377>&-&'AB-?&'B2-K:UM?FL;60;9;J;'R
MX4\@#KD_7H*\ZOKV?4M0N;ZY;=/<RM-(1_>8Y/\`.N[!Q:3;/%S:K"I52CK9
M:E>BMOPAHUOX@\6Z=I-T\B07,A5VB(#`!2>,@^E>S_\`"B/#7_/_`*K_`-_4
M_P#B*ZIU(Q=F>2?/M%?07_"B/#7_`#_ZK_W]3_XBC_A1'AK_`)_]5_[^I_\`
M$5'MX!<WOA-_R3+1_P#=D_\`1KU\WZ]_R,>J_P#7[-_Z,:OK#P[H5MX9T&VT
MBSDED@MPP5I2"QRQ;G`'<U\GZ]_R,>J_]?LW_HQJBB[RDP1GUO\`@;_D?O#_
M`/U_Q?SK`K?\#?\`(_>'_P#K_B_G71+X6,^M:***\TDYWQ[_`,B!K_\`UXR_
M^@FODVOK+Q[_`,B!K_\`UXR_^@FODVNO#_"QH*]2^`__`".6H_\`8//_`*,2
MO+:]2^`__(Y:C_V#S_Z,2M:OP,&?05%%%>>(\E^/?_(MZ3_U^G_T6U>"U[U\
M>_\`D6])_P"OT_\`HMJ\%KNH?`-!117LWPI\">'/$OA&2^U;3OM%R+N2,/YK
MK\H"X&%('<U<YJ"NQGC-%?3W_"I/!'_0%'_@1+_\51_PJ3P1_P!`4?\`@1+_
M`/%5E]8B*Y\PUZ9\#/\`D>[G_KP?_P!#2O4O^%2>"/\`H"C_`,")?_BJU-"\
M">'/#5^U[I.G?9[AHS&7\UV^4D$C#$CL*F=>,HM(+G14445RB/FSXQZ"VD>.
M9;U4Q;:D@G0XXWC"N/KT/_`J\^KZL\>^$(O&7AN2RRJ7D1\VTE/\,@'0^Q'!
M_/M7RS=VEQ87DUG>0O#<P.4EC<8*L.U=U&?-&W8:(065@RL58'(8=0>QKZ=\
M`?$/3_%FF003SQPZS&H6:W<X,A'\:>H/7`Z5\Q4=P>X.0?2JJ4U-`?:E<)\0
M_B)8^%M+GM;.XCFUJ52D,*'=Y1/\;^F.P/4U\YG6-5,7E?VI?^7C&S[2^/RS
M5+N3W/)/K64<.D[MA8"2Q)8EF)R2>I/K115G3]/NM5U&WT^QA,UU<.$C0=R?
M7T`ZD]@*Z!D*32QP/`DKK#)C?&K$*V#D9'0\TRK%]'##?30V\GFPQ.460?\`
M+3'!8>Q.2/;%5Z`"BM7PWH4_B7Q#9Z/;N(Y+EB#(5R$4`DL1WP!7IO\`PH&\
M_P"AB@_\!#_\54RJ1B[-@>.T5[%_PH&\_P"AB@_\!#_\50?@#>XX\0P9_P"O
M4_\`Q53[:'<5SQVBI+B"2UN9K>92LL,C1NI[,IP?U%1UH,WM1UTZCX-T72I&
MS-ID\ZK[Q/M*_D=P_*L&BBA*P"-]QOI7U_X6_P"11T7_`*\(/_1:U\@-]QOI
M7U_X6_Y%'1?^O"#_`-%K7/B=D)G,?%+P0/%>@_:K.,'5K)2T&!S*O\4?X]1[
M_4U\T<C@@@C@@C!%?:E>`?&3P1_9.HGQ'I\6+*[?%TBCB*4_Q?1OY_6IH5/L
ML$>54445UC+%EJ5]I-R+S3KN:UN4!VRPMM/T]Q['BOL*S19K6VN)$5IFB4ER
MHSG`KXS?_5M]*^S=/_Y!MK_UQ3^0KEQ/03/D36M8U'6]2DN=3O9KN8,RJTK9
MVC/0#H!]*SZ?-_Q\2_\`71OYFF5TK89UGPR_Y*3H?_79O_1;5]45\K_#+_DI
M.A_]=F_]%M7U17)B/B0F%%%%<X@KX[U[_D8]5_Z_9O\`T8U?8E?'>O?\C'JO
M_7[-_P"C&KIPV[&C/K?\#?\`(_>'_P#K_B_G6!6_X&_Y'[P__P!?\7\ZZ9?"
MQGUK1117FDG.^/?^1`U__KQE_P#037R;7UEX]_Y$#7_^O&7_`-!-?)M=>'^%
MC05ZE\!_^1RU'_L'G_T8E>6UZE\!_P#D<M1_[!Y_]&)6M7X&#/H*BBBO/$>2
M_'O_`)%O2?\`K]/_`*+:O!:]Z^/?_(MZ3_U^G_T6U>"UW4/@&@KZ&^!\L:>`
MI0\BJ?MTO!..RU\\T552'.K#/M#[1#_SVC_[Z%'VB'_GM'_WT*^+\48K'ZMY
MBL?:'VB'_GM'_P!]"C[1#_SVC_[Z%?%^*:P^1OI1]6\PL?:P((!!R#T-%9/A
M?_D4=%_Z\(/_`$6M%<K$:U<5XZ^&^F^,X_M`86>JQKM2Z5<AQV5QW'OU'Z5V
MM%-2<7=`?*.O?#_Q/X=D?[9I<LL"]+BU!EC(]<CD?B!7,%@&*D@,.H/6OM6J
M-WHVEWY)O--L[@GJ9H%?^8KH6(?5#N?'.1ZTFY0<;AGZU];GP1X59MQ\.Z7G
M_KU3_"KEKX>T6Q8-::180,.ACMD4_F!5?65V"Y\O^'_`OB/Q+*@L--E6!CS<
MSJ8XE'KD]?PS7J.H^%[#X6?#_4+V*0W6NWD?V1;K9]TOP0@_A`&3ZG'/I7L-
M!`/49K*59R?D%SXL$3@`"-\#_9-+Y<G_`#S?_ODU]H[5_NC\J-J_W1^5:?6?
M(+GA'P(T4S:YJ6L2QD+:PB",L,?,YR<?0*/^^J]XH``Z"BL)SYY7$%%%%0!\
MR?%G1&TGX@WKQQ-Y-\JW2$#(RW#?^/`G\:XCRY/^>;_]\FOM$@'J`:-J_P!T
M?E71'$65K#N?%WER?\\W_P"^31Y<G_/-_P#ODU]H[5_NC\J-J_W1^55]9\@N
M?%K1R;&_=OT_NFOKWPOQX2T7/_/C!_Z+6M7:O]T?E2UE4J\ZV$%5=1T^UU;3
MKC3[V(2VUPACD0]P?ZU:HK(#Y)\6^%;SPGXAN-+G5Y(Q\]O-M.)8ST/U['W%
M8?ER?\\W_P"^37VB0#U`-&U?[H_*NE8AVU0[GQ8\<FQOW;]/[IK[,T__`)!M
MK_UQ3^0J?:O]T?E2UG4J\]M!'QA-&_VB7]V_^L;^$^IIGER?\\W_`.^37VCM
M7^Z/RHVK_='Y5K]9\AW/EGX9HX^)&ADHX'G-R5/_`#S:OJ>DV@=A^5+6-2?.
M[B"BBBLP"OCW7HW_`.$CU7]V_P#Q^S?PG_GHU?85)M7T'Y5I3J<G0#XN\N3_
M`)YO_P!\FM_P,CCQ[H!*.!]OBZJ?6OK+:O\`='Y4;0.P_*M7B+JUAW%HHHKF
M$<[X]!/@#7@`2?L,O3_=-?)_ER?\\W_[Y-?:76DVK_='Y5M3J\BM89\7>7)_
MSS?_`+Y->H_`A67QCJ.Y6`_L\]01_P`M$KZ`VK_='Y4``=`*J=?FC:P7%HHH
MKG$>3?'I2WAO2=JD_P"FGH,_\LVKP;RY/^>;_P#?)K[2(!ZC-)M7^Z/RK>%;
MDC:P[GQ=Y<G_`#S?_ODT>7)_SS?_`+Y-?:.U?[H_*C:O]T?E5_6?(+GQ=Y<G
M_/-_^^31Y<G_`#S?_ODU]H[5_NC\J-J_W1^5'UGR"Y\7>7)_SS?_`+Y-(T<F
MQOW;]/[IK[2VK_='Y4;5_NC\J/K/D%S+\+\>$M&S_P`^,'_HM:*U:*Y6(***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`.7^(Y*_#K7BI((M&P0<&OG;PIX
M6UKQC=W-MI=RBR6\8D?SYV48)QQ@&OHCXD?\DYU[_KT:O`O`'C=?`^HWMVU@
M;S[3$L>T2^7MP<YS@YKJHWY'R[C-:]^$OC?3;26[26*;RE+E;>\?>0.>`0,G
MVS71_!SQWJ=[JQ\.ZI=27<<D326LLK;G0KU4D\D8Y&>F*AU+X]7%Q830V&A+
M;W#J5666YWA,]]H49_.F_`WPY#+J4^ORWEN\L$;0Q6R2`R*6ZNX[#`P/7)IR
MYN1\Z`Z_XK^$-<\5Q:2NBB,FV:4R[Y_+X8+CZ]#72^!M)O="\%Z9INH[?M<"
M,LFU]XR6)Z]^"*\]^/5Q/;P:!Y%Q-%N>?/ER%<\)UP:ZSX?ZE'8?"73M2OYG
M,4%M)++([%CA68GD]>E9-/V:`[>D#!AD$$>U?-$^K>+?BOXE:SM)I(X#EUMA
M*4A@C!ZOC[QY'/.3TIVN>#?%WPV$.K0:D?)WA3<64K`(QZ!U/4'WR*?L>C>H
M6/I:ODJZM+[5_'-WIEI.PGN=1EBCWRLJY,C8R>PKZ%^''C/_`(3/PX;B=534
M+9_*NE3@$XR&`[`C]0:\#LM0M]*^*8U"\<I;6VKR22L%+$*)&[#DU5%.+DNH
M(W;CX0^.;6%I8VAF*#.R&];<?ID#G\:G^&/CW5]*\36NB:G=3W%A=2_9]EPQ
M9K>0G`P3R!G@CW]J]&NOC1X.@@9X;FZN)`/ECCMG!8^F6``KQGPS%=>+/BA:
M7$<.U[C4/MLJITB0/O;GVZ?4CUJTY2B^=`=]\?9'1]`V2.F?/SM8C^YZ5WOP
MR8GX;:&S,2?L_)8Y_B-<!\?_`+_A_P#[;_\`LE8GASP;XM\>>%;/_B:QV.C6
MB&&TA;=B7!.6*KUYR,GTX%1RITE=V`^AP01D'(HKYF\(ZSK7@7X@Q://<OY/
MVQ;2[M_,+1L&(`90>AY!!XKV?XE7_B2T\."'PQ97,]Y</LDFMU#-`F.2!UR>
M`,=.:SE2:DE?<1V)95(!8`GU-+7SOI/P@\3^(-,75+W41:3S998;SS&EZ]7/
M5<_C2?#'Q#K.A>/H?#MW=2O:RS26LUO)(75)%!^9<].5QQU!INDK.SO89]$T
M$@8R<9KP_P"/-S<0:KHH@N9X0T$N1'(RY^9?0US-MX4\;_$#2XM9C=7MX(UM
M[5)K@IE4&WY!]1RQ(R<T1I7BI-V`^EJ"0!DG`]Z^?/B_#=:(_AK3H[ZZS#IQ
MC=Q.V7((!8G/)IUIX+\9_$308-7N=6BAM1$$LK21WPRJ-H.!P,XZG)/7IBA4
ME92;T`^@:3(SC(SZ5\L^%/%'BRQ>3P]HMW)YNH.((XY&W>2^>60G[IQG)Z=^
MHJ[XR\!>(/!<%MK%UJWVEII=C3PRN'CDP2/F)R<X//M3]A9V;"Q]-4$X&37%
M?#'Q)>>(O`L-Y?%IKNW=X)'`^:4KT/U((_&O+[SP_P"/_B!XKFBU.&\TV`[I
M$%QN6"%`<!5"\,W3W/)Z5"IZM-VL(^A`P89!!'M2U\P>*/"FO_#2^L;B/5S^
M_+&&>U=D(9<9#*?J/4&OH+P9K,WB'P=I>JW`43W$`,NT8!<$@D#Z@T3I\J33
MN@-VOGKXX7=S!XWA6&ZGB7[`AVQRLHSN?L#7T+7SI\=/^1YA_P"P>G_H;U5#
MXQH]V\,,S>$]&9B68V,!))R2?+6M6LGPM_R*.B_]>$'_`*+6M:LGN(\Z^+'C
M?4_"%C8PZ6D2SWWF#[1(-WE!=OW5Z$_-WZ>AK>^'=Y<W_@#1[N\GDGN982TD
MLC99CN/)->)?%KP]J6D^*)=1O+E);;4IY)+6-9&8QJ`N001@=1TKJOA%X/UN
MWO-.\2RWT;:5-;2!+<3.6&>!\N-O4'O6[A'V:=QGM59GB!L^&=5*M_RYS8(/
M^P:\%\>^+M9\9>,'T'2II19)<?9;>WA?:)W!P7<]QD'KP`,U;O?A_P",?`>B
M7.KV>K13PB%EO;6(L5\MAAB5/#`9Z\$=14JE:UWJ`WX$2R/XQNP\DC#^SFX9
MB?XTKZ$KYZ^!`QXTO0.@T]O_`$8E?0M%?XP84445B(****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`.6^)'_).=>_Z]&KR'X*Z/INLZYJL6IV%O>1QVR,BS
MQAPIW'D9KV?QS876J>"-8L;*$S74]LR1Q@@%CZ<\5X+IW@;XCZ1*\NF:??V<
MDBA7:"Y1"P]#AJZ*5G!J]AGNEU\//"%W"T4GAZP4,,;HX@C#Z%<$5\_>&IW\
M/?%.UCTNX:6*/4C:*ZG_`%T1DV$'UR.?J,UM2^&_BU>1-!.VL/$XPROJ"X(]
M_GKJOAO\)K[2-9AUOQ!Y226V3;6D;A\/C&YB...P&>>>U4K0B[RN!'^T!_J/
M#_\`OS_R2K4,<DG[-16($L+)F./[HE)/Z`U<^,GAC6O$D.C#1[![LP/,9=K*
MNW(7'WB/0UT_@71I[+X=:=I&KVGERB!XIX'(/#,V0<''(-1S)4X^H'FWP"F@
M74M<A8C[2\43IZE`6!Q^)7\Q7H/Q6F@A^&NL"=E'F1JD8/=RZXQ[YY_"O+M9
M^%WBOPEK?]H^%7FN8$8F"2W<">,'^%E/WO3C.>XJM<^'?B;XZNH(-7@NEAC/
M#7@6&*/MNVCJ?H":MQC*?/?0#?\`@!'+YVO2\^3B!?;=\Y_D?UKSZWTR#6?B
M<VF7+.L%UJTL4AC.&`,C=#ZU]'^#O"EIX.\/Q:9;,9'R9)YB,&60]3CL.``.
MP%>/:/X"\46WQ0@U2;1Y4L5U5YS,9$P$+L0V-V>A%$9IRDP.S7X%^%0<FYU1
MAZ&=?_B:[#PWX/T/PG`\>D62Q-)_K)F8O(_U8\X]NE;M%<[G)Z-B/$_C_P#?
M\/\`_;?_`-DKOOA>`/AKH6!_RP)_\>-<Q\9/"^M^)&T8Z/I[W?D>=YNUU7;G
M9CJ1Z&NR\`Z==Z3X%TBPOX#!=00[9(R02IW'TXK237LDAGA'C'CXU7./^@G;
M_P#M.O7/B?X^F\&6%K!811R:C>;MAE&5B1<98CN<D`#_``KA/$_@7Q-??%.?
M5;;2)9+%KZ"43"1`"J[,G!;/&#VKL?BUX%OO%=E9WVE*LE]9;E,#,%\U&P3@
MGC(([]<FK;BW&X'*Z5X>^)/CK3HM1O?$K6-A=+N10Y0NA[A(P./J:X_P99_8
M?B]I]EYWG?9M1DB\TC&_:'&?QQ72:"WQ:M]+C\/6%A/:VZ`QI/<Q*IA7T#D]
M!VX)]*AT?X=^*_#/Q`L+L:=)?6EK=([W43J`ZD?,P!;/&X]?2KO:Z;0%_P"/
MO_(6T/\`ZX3?^A+7IGPWC$7PYT%5&`;16_$\G^=<9\8_">N^(]1TF32-.DNT
MAAD60JZC:25QU(]#7?\`@NQN=,\%:/97D1AN8+5$DC)!*L!R..*QDU[-(#R+
MX^?\C!HW_7I)_P"ABO6?`BA?`.@@#`^PQ?\`H(K@/C%X1U[Q'K.F3:1ILEW'
M#;NDC*ZC:2P(')%>C^$K.XT_P?H]G=Q&*X@LXHY(R02K!0".*)M>SB@/G[X;
M*&^+UGD9Q<7)'UVO7IWQS_Y$*#_K_B_]!>N3\">!O$VE?$JVU.^TF6&R2:=F
ME,B$`,K@<!L\Y%=Y\6]#U/Q!X/BL]*M&NKA;R.0QJP!VA6R>2/45<Y+VD7<#
M'^#=[#IWPRO[ZX)$-O=3RR$?W512?Y5RMKXU\??$;6YK'P_<1Z;`J^850A?*
MCS@%G())^GY5W'PX\*7UG\.M0T/7+5[22[FG5D+*3L=%7(P2/7\J\UL?"WQ"
M\`>())M(T^6X;:8_.@C$L4R9XR,Y'0'G!%-<KE+N!4^(?A#5_#4>GW6M:XVI
MW=XT@Y9VV!0#P6.3U]!7M?PL&/AGH?\`UQ;_`-#:O+?$7@CXB>*+--;U>,3W
M@<11:>C*ICC()+8SM'('&23WZ5ZK\-;+4M,\#6.G:K9/:75J7C*.P.Y=Q((P
M3V/Z4JKO!*^H'6U\Z?'3_D>8?^P>G_H;U]%UXG\6O!?B+Q!XOBO-*TN2ZMQ9
MI&75T`W!F)')'J*B@TIZ@CU;PM_R*.B_]>$'_HM:UJ^<H=`^+=O#'#"=9CBC
M4(B+?*`J@8``W]*LVFC?%M;ZV,TNM>4)D,F;Y2-NX9S\_IFFZ2_F0&S\?^OA
M_P#[;_\`LE=[\+_^2:Z%_P!<#_Z$U8GQ@\(:GXGTFPN-)A^T7%E(Y:`$!G1@
M,[<\$@J.*Y[X7V_CVPURPT_4;2_M]`MTE!CFC5%4D$CD_,?F_G3TE22OL'0X
MKX=.MI\6=/%U@,+J>,[O[Y5P/QS7T1XJFA@\(ZQ)<,!$ME-N)Z8V&O)OB/\`
M"[5?[>FU_P`-Q-.L\GG2P1-MDBESDLG(R">>.0?TJV^A_$WQO;IIFNS7-II4
M?,K3QI&TF.0,#!<Y`Z\=Z<U&=I7`I_`<$>,[P'K_`&<W_H:5]#5XO\(?!WB'
MP]XINKO5]+DM('LFC5V=&RV]3C@GL#4'Q-\)^,-7\:S7>C6E[)9&")5:&Y"+
MN`.>-PI5$IU-P/;Z*9""L$:M]X*`?KBBN<0^BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>